EXICURE INC (XCUR)

US30205M2008 - Common Stock

2.62  -0.06 (-2.24%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

EXICURE INC

NASDAQ:XCUR (10/21/2024, 3:28:16 PM)

2.62

-0.06 (-2.24%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month-4.46%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap4.53M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

XCUR Daily chart

Company Profile

Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. The company is headquartered in Chicago, Illinois and currently employs 6 full-time employees. The company went IPO on 2018-05-09. The firm is into exploring strategic alternatives to maximize stockholder value. The company is engaging in a broader exploration of strategic alternatives. This effort involves exploring growth through transactions with potential partners that see opportunity in joining an existing, publicly traded organization. The firm is exploring transactions in industries unrelated to its historical operations. The company does not generate any revenues. The company wholly owned subsidiary is Exicure Operating Company that holds all material assets and conducts all business activities and operations of the Company.

Company Info

EXICURE INC

2430 N. Halsted St.

Chicago ILLINOIS 60614

P: 18476731700

CEO: David A. Giljohann

Employees: 6

Website: https://www.exicuretx.com/

XCUR News

News Imagea month ago - Exicure, Inc.Exicure, Inc. Receives Extension from Nasdaq Hearings Panel
News Imagea month ago - Exicure, Inc.Exicure, Inc. Announces Proposed Settlement of Securities Class Action Litigation
News Image2 months ago - Exicure, Inc.Exicure, Inc. Announces 1-for-5 Reverse Stock Split
News Image2 months ago - Exicure, Inc.Exicure, Inc. Announces Additional Adjournment of Special Meeting and Information for Reconvened Special Meeting
News Image2 months ago - Exicure, Inc.Exicure, Inc. Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting
News Image2 months ago - BusinessInsiderXCUR Stock Earnings: Exicure Reported Results for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Exicure (NASDAQ:XCUR) just reported results for the second quarter of 2024.Exic...

XCUR Twits

Here you can normally see the latest stock twits on XCUR, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example